Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosangela Frita

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Organic & Biomolecular Chemistry|November 29, 2017
New active leads for tuberculosis booster drugs by structure-based drug discoveryNatalie J Tatum, John W Liebeschuetz, Jason C Cole, et al.
Molecular Microbiology|July 20, 2007
A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosisSharon L Kendall, Mike Withers, Catherine N Soffair, et al.
Genome Biology|December 15, 2007
Quantification of global transcription patterns in prokaryotes using spotted microarraysBen Sidders, Mike Withers, Sharon L Kendall, et al.
European Journal of Medicinal Chemistry|February 21, 2019
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2Hugues Prevet, Martin Moune, Abdalkarim Tanina, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
Tuberculosis (Edinburgh, Scotland)|September 13, 2018
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymeraseGiorgia Mori, Beatrice Silvia Orena, Clara Franch, et al.
Nature Communications|April 7, 2026
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosisZainab Edoo, Camille Grosse, Thomas Maitre, et al.
Science Translational Medicine|May 4, 2022
The small-molecule SMARt751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosisMarion Flipo, Rosangela Frita, Marilyne Bourotte, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Organic & Biomolecular Chemistry|November 29, 2017
New active leads for tuberculosis booster drugs by structure-based drug discoveryNatalie J Tatum, John W Liebeschuetz, Jason C Cole, et al.
Molecular Microbiology|July 20, 2007
A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosisSharon L Kendall, Mike Withers, Catherine N Soffair, et al.
Genome Biology|December 15, 2007
Quantification of global transcription patterns in prokaryotes using spotted microarraysBen Sidders, Mike Withers, Sharon L Kendall, et al.
European Journal of Medicinal Chemistry|February 21, 2019
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2Hugues Prevet, Martin Moune, Abdalkarim Tanina, et al.
European Journal of Medicinal Chemistry|June 7, 2020
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screeningLéo Faïon, Kamel Djaout, Rosangela Frita, et al.
Science (New York, N.Y.)|March 18, 2017
Reversion of antibiotic resistance in <i>Mycobacterium tuberculosis</i> by spiroisoxazoline SMARt-420Nicolas Blondiaux, Martin Moune, Matthieu Desroses, et al.
Npj Antimicrobials and Resistance|May 30, 2026
Exploiting DprE2 pathway redundancy to enhance potency and overcome resistance to pretomanid in Mycobacterium tuberculosisKamel Djaout, Aurore Dreneau, Léo Faion, et al.
Tuberculosis (Edinburgh, Scotland)|September 13, 2018
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymeraseGiorgia Mori, Beatrice Silvia Orena, Clara Franch, et al.
Nature Communications|April 7, 2026
Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosisZainab Edoo, Camille Grosse, Thomas Maitre, et al.
Science Translational Medicine|May 4, 2022
The small-molecule SMARt751 reverses <i>Mycobacterium tuberculosis</i> resistance to ethionamide in acute and chronic mouse models of tuberculosisMarion Flipo, Rosangela Frita, Marilyne Bourotte, et al.
Pageof 2